The FDA approved a reformulated version of Zogenix's ($ZGNX) painkilling Zohydro ER designed to be abuse resistant, marking another step in the battle against opioid abuse and another chapter in a long-running battle over the controversial and ... Fierce Drug Delivery, 3 weeks ago
Zogenix (ZGNX) Stock Rises Today on Zohydro FDA Approval - TheStreet.com, 3 weeks ago
FDA Okays Abuse-Deterrent Zohydro ER - Dermatology Online Journal, 3 weeks ago
3 images for "Zohydro"
Zogenix Inc. has received U.S. approval for a new formulation of its much-debated painkiller Zohydro that is intended to be harder to abuse, though the company is still working on studies needed toYahoo! UK and Ireland, 3 weeks ago
More from: Town Hall, Town Hall...and 2 other sources
:50:21 GMT 2015 Informa plc. All rights reserved. This site is owned and operated by Informa plc ("Informa") whose registered office is Mortimer House, 37-41 Mortimer Street, London, W1T 3JH. Registered in England and Wales. Number 3099067. UK ...Scrip, 3 weeks ago
The US Food and Drug Administration (FDA) has accepted for review the new drug application (NDA) for Teva Pharmaceutical's hydrocodone bitartrate extended-release (ER) tablets formulated with its abuse deterrence technology (CEP-33237) for pain ...Pharmaceutical Business Review, 2 days ago Teva Announces FDA Acceptance for Review of NDA for its Investigational Twice-Daily Hydrocodone Bitartrate Extended-Release Tablets with Proprietary Abuse Deterrence Technology World Energy Source, 3 days ago US FDA accepts for review Teva's NDA for hydrocodone bitartrate ER tablets with proprietary abuse deterrence technology PharmaBiz, 1 day ago Teva Pharmaceutical Industries Announces FDA Acceptance For Review Of NDA For Its Investigational Twice-Daily Hydrocodone Bitartrate Extended-Release Tablets With Proprietary Abuse Deterrence Technology BioSpace, 2 days ago
Teva Pharmaceutical Industries recently announced that the FDA has accepted for review a New Drug Application (NDA) for its investigational formulation of extended-release hydrocodone bitartrate with abuse-deterrent properties. The NDA seeks the ...Pharmacy Times, 2 days ago FDA Accepts Teva's NDA for Abuse-Deterrent Opioid PharmaceuticalProcessing, 2 days ago
The small cap biotech & biopharma spaces are inherently volatile but have delivered huge winners to my portfolio over the past six months. I believe in building a well-diversified portfolio by taking small stakes across a myriad of promising ...Seeking Alpha, 3 days ago
Pharma bigwig Pfizer ($PFE) announced that the FDA has agreed to review the New Drug Application of its abuse-deterring extended-release opioid capsules, dubbed ALO-02. The capsules' pellets contain the opioid receptor antagonist naltrexone ...Fierce Drug Delivery, 1 week ago UPDATED: FDA agrees to review Pfizer's abuse-deterring opioid candidate Fierce Drug Delivery, 1 week ago
Feb. 18, 2015 2:09 PM ET | About: Biogen Idec Inc. (BIIB), Includes: AMGN, BAX, JNJ, LLY, MS, PFE by: Investing Healthcare Summary BIIB revenue growth is expected to decelerate this year versus years past. Catalysts in treating pain and ...Seeking Alpha, 1 week ago
The FDA recently accepted for review New Drug Applications (NDAs) for Collegium Pharmaceuticals extended-release oxycodone formulation (Xtampza ER) and Pfizer's extended-release oxycodone hydrochloride and naltrexone hydrochloride (ALO-02), a pair ...Pharmacy Times, 1 week ago Abuse-Deterrent Morphine Under FDA Review Pharmacy Times, 2 weeks ago
WASHINGTON, D.C. - Prescription drug abuse continues to be a serious issue for families and communities across our nation. As part of their efforts to fight this alarming epidemic, Congressman Stephen F. Lynch (MA-08) and Congressman Harold "Hal" ...Noodls, 2 weeks ago
on your WebpageAdd Widget >Get your members hooked!